Cytidine-phosphate-guanosine oligodeoxynucleotides in combination with CD40 ligand decrease periodontal inflammation and alveolar bone loss in a TLR9-independent manner Local administration of toll-like receptor 9 (TLR9), agonist cytidine- 
Introduction
Periodontitis is characterized by inflammation and alveolar bone loss, which are closely related to bacteria-induced host immune responses. 3 Conventional therapies for periodontitis focus on clinical methods, such as removal of dental plaque and calculus, reduction of infection and periodontal surgery. Although these treatments are sufficient to treat periodontal diseases in many cases, the host immune response has been sustained in an imbalanced state. Recently, researchers have explored immune mechanisms and treatment strategies associated with periodontitis by looking for novel inflammatory pathways, 8 regulating host innate and adaptive immune responses, 9 and exploring immune mechanisms that inhibit alveolar bone loss. 29 Toll-like receptors (TLRs), a class of immune molecules closely related to periodontitis, consist of at least 13 proteins working as key pathogen recognition receptors (PRRs) in innate immunity system and respond to many kinds of microbial products and injuryinduced endogenous products. 13 Of these receptors, TLR9 is unique for its engagement in both microbial nucleic acids and danger-associated molecular patterns (DAMPs), and communication with other TLRs. 5 TLR9
can activate pro-and/or anti-inflammatory signaling pathways and mediate inflammatory responses in periodontitis pathogenesis. 8 In another study using oral gavage model of periodontitis, Kim, et al.
11 (2005) found that TLR9 Knockout (KO) mice show better resistance to periodontal inflammation and TLR9 can regulate TLR2-and TLR4-triggered inflammation by downstream signaling pathways.
TLR9 is not only activated by microbial nucleic acids, but also by synthetic cytidine-phosphateguanosine (CpG) DNA motifs. 11 At the molecular level, internalization of CpG activates TLR9 mediated sequence recruitment signals of MyD88, interleukin receptor associated kinase (IRAK) and TNFreceptor associated factor 6 (TRAF6), which activate downstream transcription factors (NF-κB and AP-1)
causing the induction of proinflammatory cytokines. 9 Some studies have suggested that preventive therapy in mice using synthetic CpG can protect them against diverse infections. 
Bone morphometric analysis
The defleshed maxillae were bleached with 3% hydrogen peroxide for 8 hours and stained with 1% toluidine blue. The degree of alveolar bone loss was measured by Nikon microscope (SMZ745T, Nikon Instruments Inc). Images of the palatal alveolar bone of each maxilla were acquired, and the specific area presenting alveolar bone loss was measured by Image J software (NIH). The defined method of the area has been previously described. 16 It was formed 
CD1d
hi CD5 + B cell expansion was induced by CD40L and inhibited by CpG in vitro but not in WT mice ( Figure 3D ).
IL-10 mRNA expression and protein expression were increased by CpG stimulation in B cells from both WT and TLR9 KO mice
The levels of IL-10 mRNA and protein expression Gingival IL-10 mRNA expression was increased and RANKL and IFN-γ mRNA expression was decreased after local administration of CpG+CD40L in WT mice and TLR9 KO mice.
The levels of gingival mRNA expression of IL-10, OPG, RANKL, IFN-γ, IL-1β and TNF-α were measured by qRT-PCR. In both WT and TLR9 KO mice, the mRNA level of gingival IL-10 expression was significantly increased and the mRNA levels of gingival RANKL and IFN-γ was significantly decreased Figure 4 -CpG increased IL-10 mRNA expression and protein secretion in spleen B cells from WT and TLR9 KO mice. Purified spleen B cells separated from WT mice and TLR9 KO mice were cultured with CD40L (0.1 μg/ml), CpG (1 μM) +CD40L (0.1 μg/ml) for 48 h. The levels of IL-10 mRNA expression (A) and protein secretion (C) were detected by qRT-PCR and ELISA, respectively (mean±SD, n=4 WT mice or TLR9 KO mice per group, *p<0.05, **p<0.01). Purified spleen B cells separated from WT mice and TLR9 KO mice were cultured with CpG-Low (0.1 μM), CpG-Med (1 μM) and CpG-High (10 μM) for 48 hours. The levels of IL-10 mRNA expression (B) and protein secretion (D) from cultured B cells were detected by qRT-PCR and ELISA, respectively (mean±SD, n=4 WT mice or TLR9 KO mice per group, *p<0.05, **p<0.01) Figure 5 -CpG+CD40L reduced bone loss in ligature-induced experimental periodontitis of WT and TLR9 KO mice. Silk ligatures were tied around the maxillary secondary molars on day 0 and injection of CpG (1 μM)+CD40L (0.1 μg/ml) or PBS was performed in palatal gingiva on days 3, 6 and 9 in WT mice and TLR9 KO mice. Maxillae were collected on day 14, and the area of palatal alveolar bone loss around the maxillary secondary molars was pictured (A) and analyzed (B). Data were presented as the bone loss area (square millimeter) determined at a magnification of 30X (means±SD, n=4 WT or TLR9 KO mice per group, *p<0.05, **p<0.01, compared with PBS injection group) Thus, the combination of CD40L with CpG will both induce B10 activation and maintain B10 population.
The synergy effects were shown in B cells from WT mice in vitro and ligation-induced periodontitis model in WT mice in vivo in our previous study. 29 Moreover, the effects of different concentration of CpG+CD40L on decreasing ligature induced periodontitis have been previously studied. 29 The previous experimental results showed that low concentration of CpG+CD40L
(1 uM of CpG+0.1 ug/ml of CD40L) had a higher inhibitory effect on ligature induced periodontitis and alveolar bone loss than that of high concentration of CpG+CD40L (10 uM of CpG+1 ug/ml of CD40L). Thus, low concentration of CpG+CD40L (1 uM of CpG+0.1 ug/ml of CD40L) was selected for our experiments.
In summary, our study investigated the effects of CpG+CD40L on B10 cell population and activation from both WT and TLR9 KO mice, indicating a possible TLR9 independent mechanism of this synergy effect.
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Conclusions
In conclusion, our study demonstrated that local administration of CpG+CD40L can decrease periodontal inflammation and alveolar bone loss in a TLR9-independent mechanism. The unknown mechanism remains to be investigated in the future, which is important to develop immunological interventions for treatments of periodontitis.
